Chardan raised the firm’s price target on Lexeo Therapeutics (LXEO) to $17 from $15 and keeps a Buy rating on the shares following the regulatory and data update for LX2006. The firm believes the FDA’s willingness to allow pooling of data from the ongoing Phase I/II studies support accelerated approval. Lexeo also shared updated data from the Phase I/II trials of LX2006, showing signals of sustained and dose-dependent improvements in left ventricular mass index, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz
- Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright
- Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target
- Lexeo Therapeutics price target raised to $20 from $9 at Leerink
- Morning Movers: IntercontinentalExchange up after $2B investment in Polymarket